Severe Acute Respiratory Syndrome News and Research

Latest Severe Acute Respiratory Syndrome News and Research

SARS-CoV-2 detected in Santiago, Chile wastewater with very little loss of viral RNA

A preliminary report from Chile describes the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in sewage as a sensitive method to assess the circulation of viruses within a community.

7 Jul 2020

Viral and bacterial co-infections are pervasive in severe COVID-19 patients

A large group of researchers from China recently characterized microbial co-infections in the respiratory tract of hospitalized coronavirus disease (COVID-19) patients and demonstrated a high prevalence of both viral and bacterial co-infections – particularly in individuals presenting with severe disease.

6 Jul 2020

Airborne spread of SARS-CoV-2 possible and should not be ignored

Researchers at the National Institute for Public Health and the Environment in the Netherlands say that airborne transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is possible and should not be discounted.

6 Jul 2020

COVID-19 risk halved when airplane middle seats empty, expert statistician says

As the coronavirus cases skyrocket, many countries have started to ease lockdown measures to save the ailing economy. Restaurants, malls, recreational centers, and transportation are slowly returning to normal operations. However, one of the most heavily impacted sectors amid the pandemic is the aviation industry.

6 Jul 2020

WHO urged to recognize airborne transmission of COVID-19

Now, a team of international scientists, including 239 health experts from 32 countries, has written an open letter to the WHO urging the organization to revise its recommendations for the spread of SARS-CoV-2, due to mounting evidence that the disease is airborne for more extended periods than the WHO advisory.

6 Jul 2020

Oxford COVID-19 vaccine trials move to stage 3 human trials

The technical name of the vaccine is ChAdOx1 nCoV-19 (AZD1222), as it is made from a virus called ChAdOx1, which is a weakened and non-replicating version of a common cold virus (adenovirus). The vaccine has been engineered to express the SARS-CoV-2 spike protein.

5 Jul 2020

Research suggests protective effect of influenza vaccine against COVID-19 severity and mortality

A new study involving over 92,000 patients with COVID-19 in Brazil shows that the odds of severe disease, ventilatory support requirement, and death are reduced with a recent trivalent flu vaccine. This seems to indicate that these vaccines should be used as widely as possible to reduce the risk of severe COVID-19, especially among high-risk groups. The study is published on the preprint server medRxiv* in June 2020.

5 Jul 2020

Diagnosis of COVID-19 by RT-LAMP assay in 25 minutes

Even as COVID-19 continues its inexorable march, taking hundreds of thousands of lives and causing nearly 11 million cases, the diagnosis of the infection is still not sensitive or specific enough. Now, a new study by scientists at the Francis Crick Institute and published on the preprint server medRxiv...

3 Jul 2020

Mutated European strain of coronavirus more contagious but less potent

The coronavirus pandemic is far from over as it actively spreads across the globe. The infection toll has reached a staggering 10.84 million people since it emerged in late December 2019 in Wuhan City, China. The virus that has left the city has now spread to 188 countries and territories and has mutated, becoming more infectious.

3 Jul 2020

Markers of vascular damage in COVID-19

A new study by researchers at Yale University and published on the preprint server medRxiv reports on the plasma levels of biomolecules that reflect vascular damage in COVID-19.

2 Jul 2020

Effectiveness of NPI's in COVID-19 - conclusions are predictable, NPI's work

Now, a new study published on the preprint server medRxiv* looks at how the effects of these NPIs can be quantified in order to keep the public health response to COVID-19 at an adequate level. While NPIs are known to reduce the peak of the infections, in general, the researchers wanted to quantify different components separately.

2 Jul 2020

Researchers find possible cause for SARS-CoV-2 reactive T cells in uninfected individuals

The current pandemic of COVID-19 is caused by the severe acute respiratory syndrome coronavirus (SARS-CoV) -2, leading to severe pneumonia, acute respiratory distress syndrome, and death in a sizable minority of cases. However, the most significant number are asymptomatic or have only mild infection from which they rapidly recover.

2 Jul 2020

Pfizer/BioNTech COVID-19 vaccine shows promise - virus neutralizing antibodies achieved

In a recent medRxiv* paper, a research group from the U.S. and Germany showed a robust immunogenic response and a promising safety profile of the novel BNT162b1 RNA-based vaccine against coronavirus disease (COVID-19) – actively encouraging its accelerated clinical development and potential rapid production.

2 Jul 2020

New platform prioritizes synergistic drug combinations against SARS-CoV-2

Researchers in the U.S. have used a new web-based platform to help identify synergistic and antagonistic drug combinations and their underlying mechanisms of action in the context of coronavirus disease 2019 (COVID-19).

2 Jul 2020

Structure of the full SARS-CoV-2 RNA genome in infected cells

The current COVID-19 pandemic caused by a single-stranded RNA virus, thought to have jumped across species barriers to infect humans, has spread rapidly across the globe infecting over 10 million individuals. The virus, now known as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is the causative agent of COVID-19 disease. COVID-19 disease is a respiratory illness where symptoms can range from very mild to severe and include fever, coughing, a sore throat, and shortness of breath.

2 Jul 2020

SARS-CoV-2 infection modeling in iPSC-derived type 2 cells

The most fatal form of COVID-19 disease is acute respiratory distress syndrome (ARDS), caused by direct viral injury as well as indirect noxious effects caused by cytotoxic chemicals and inflammatory processes. A new study published on the preprint server bioRxiv* in June 2020 shows that this is partly due to the rapid onset of inflammation caused by the infection of type 2 alveolar cells with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

2 Jul 2020

Novavax SARS-CoV-2 vaccine candidate shows promise in animal models

A new study published on the preprint server bioRxiv in June 2020 shows that a candidate spike protein vaccine can induce neutralizing antibodies, antiviral T cell responses, and protection against infection.

2 Jul 2020

How lockdown stopped the virus in Italy

Previous studies have shown that many severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cases were tied to asymptomatic carriers or those who do not manifest symptoms of the viral infection. Now, a new study reveals that in the first Italian town hit by the virus, as much as 40 percent of the population had no symptoms of the coronavirus disease (COVID-19).

1 Jul 2020

Coronavirus immunity is higher than previously thought, study finds

Now, a team of researchers at the Karolinska Institutet and Karolinska University Hospital in Sweden has found that the number of people immune to COVID-10 may be higher than previously thought, and that antibody testing may no longer be the appropriate tool to trace it.

1 Jul 2020

Scientists find coronavirus' Achilles' heel

A team of scientists at the University of California San Francisco has found out how SARS-CoV-2, the virus that causes the coronavirus disease (COVID-19) invades proteins in the cells that serve as master regulators of key cellular processes.

1 Jul 2020